Management of Moderate Aortic and Mitral Regurgitation

Initial Assessment and Management

The European Society of Cardiology recommends regular clinical surveillance with echocardiographic monitoring every 1-2 years, combined with guideline-directed medical therapy for any concurrent hypertension or heart failure, while reserving surgical intervention for those who develop symptoms, left ventricular dysfunction, or progression to severe disease 1, 2
The American College of Cardiology suggests determining the predominant lesion through comprehensive echocardiographic evaluation, as management follows recommendations for the dominant valve pathology when one lesion is clearly more severe than the other 3, 4

Echocardiographic parameters to assess include vena contracta width, effective regurgitant orifice area, regurgitant volume, left ventricular dimensions, left ventricular ejection fraction, left atrial size, and pulmonary artery systolic pressure, as recommended by the European Heart Journal 1, 2
Exercise testing should be performed when symptoms seem disproportionate to resting hemodynamic findings, as patients with mixed moderate disease may develop functional limitations at higher flow rates that are not apparent at rest, according to the American College of Cardiology 3, 5

The European Society of Cardiology recommends ACE inhibitors or ARBs for patients with hypertension, as they reduce afterload and may provide symptomatic improvement in chronic aortic regurgitation 1, 6
If symptoms of heart failure develop, the European Society of Cardiology suggests initiating guideline-directed medical therapy including ACE inhibitors/ARBs, beta-blockers, and mineralocorticoid receptor antagonists 1, 2

Moderate aortic regurgitation requires echocardiographic follow-up every 1-2 years in asymptomatic patients with normal left ventricular function, as recommended by the European Heart Journal 1
Moderate mitral regurgitation requires clinical evaluation every 6-12 months with annual echocardiography, according to the European Heart Journal 2

The American College of Cardiology suggests valve intervention when symptoms develop that are attributable to the valve disease, with supportive clinical findings including objective evidence of functional limitation or significantly elevated atrial/ventricular pressures on exercise hemodynamic studies 3, 5
Surgical referral is indicated for aortic regurgitation if LVEF falls to ≤55% or LVESD exceeds 50 mm, and for mitral regurgitation if LVEF falls to <60% or LVESD reaches ≥40 mm, as recommended by the European Society of Cardiology and the American College of Cardiology 1, 2, 6, 10

The American College of Cardiology advises against assuming moderate disease is benign, as the combination of moderate AR and MR creates additive hemodynamic burden that may cause earlier decompensation than isolated moderate disease 3, 4
Delaying surgical referral once objective markers of left ventricular dysfunction appear can result in significantly worse outcomes, according to the European Heart Journal 1, 2